title: An open-label series using loratadine for the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors.
abstract: OBJECTIVE
  To assess the impact of loratadine as an add-on treatment of erectile dysfunctions associated with selective serotonin reuptake inhibitors (SSRIs).
  
  
  METHODS
  Nine patients diagnosed as major depressive disorder (MDD), with erectile dysfunction associated with the administration of SSRIs, completed a 2-week trial of loratadine in the dose of 10 mg/day. The International Index of Erectile Function Five (IIEF-5) was used as an assessment measure for diagnosing the presence and severity of erectile dysfunction. The 17-item Hamilton Rating Scale for Depression (HAM-D) was administered for screening the potential impact of depressive symptoms.
  
  
  RESULTS
  Baseline mean S.D.+/-IIEF-5 scores were 10.33+/-4.55 (range 5-20) and week 2 mean+/-S.D. IIEF-5 was 14.44+/-3.84 (range 10-22). Subjects had statistically significant improvement in their erectile functions on the IIEF-5 (t = -8.485; df = 8; p = 0.000) and 55% reported subjective improvement of the erectile function. No significant changes on HAM-D 17 scores were registered. Baseline mean S.D. scores were 13.66+/-2.29 (range 10-17) and week 2 mean S.D. was 13.11+/-1.96 (range 10-16) (t = 1.47; df = 8; p = 0.179).
  
  
  CONCLUSIONS
  Our findings suggest the possible role of loratadine in the treatment of SSRI-associated sexual dysfunction. They are promising, but preliminary. Thus they should be replicated in a longer large-scale, double-blind, placebo-controlled trial.
authors.affiliation: Neuropsychiatric Hospital Dr. Ivan Barbot Vinogradska 55, Popovaca 44317, Croatia. branka.aukst-margetic@zg.htnet.hr
authors.forename: Branka
authors.initials: B
authors.lastname: Aukst-Margetić
authors.forename: Branimir
authors.initials: B
authors.lastname: Margetić
mesh_terms: D000328:Adult; D003865:Major Depressive Disorder / Q000150:complications / Q000188:drug therapy; D007172:Erectile Dysfunction / Q000139:chemically induced* / Q000188:drug therapy*; D006634:Histamine H1 Antagonists / Q000494:pharmacology*; D006801:Humans; D017336:Loratadine / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D006634:Histamine H1 Antagonists; D017336:Loratadine; D017367:Selective Serotonin Reuptake Inhibitors